“We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation

Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.

There are no comments yet.

Please log in to write the first comment.